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Abstract
Stem cell therapy is a promising treatment modality for necrotizing enterocolitis. Among the many 
promising stem cells identified to date, it is likely that mesenchymal stem cells will be the most 
useful and practical cell-based therapies for this condition. Using acellular components such as 
exosomes or other paracrine mediators are promising as well. Multiple mechanisms are likely at 
play in the positive effects provided by these cells, and further research is underway to further 
elucidate these effects.
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Introduction
Necrotizing enterocolitis (NEC) is a leading cause of death in premature infants, with 
mortality remaining as high as 30% [1]. Despite extensive efforts to elucidate the 
pathophysiology of the disease, and to identify potential treatments, mortality and morbidity 
remain unacceptably high. Survivors are faced with lifelong complications including short 
gut syndrome and neurological sequelae. Treatment options for infants affected by NEC are 
limited to supportive care at diagnosis, with many babies progressing to surgical intervention 
for resection of necrotic bowel. It is important to note that although breast milk may reduce 
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the incidence of NEC, it does not eliminate it [2]. Despite decades of research, a cure for the 
disease has still not been found.
The identification of potential treatments for NEC is still hampered by an incomplete 
understanding of the precise pathogenesis of the disease. NEC is a disease that 
predominantly affects premature infants, occurring most commonly after the introduction of 
enteral feeding. Differences exist in microbial colonization of pre-term infants and term 
infants, as well as those delivered vaginally and those delivered by Caesarean-section [3]. 
The microbiome of infants who go on to develop NEC differs from that of babies that do not 
develop the disease [4, 5]. In addition, the inflammatory response is heightened in infants 
affected with NEC [6]. This combination of pro-inflammatory and infectious components 
certainly contributes to the development of disease.
Animal models of experimental NEC have been utilized over the decades to examine 
different potential therapies for the disease, including stem cell (SC) therapy. Stem cells 
have been shown in several disease models to have anti-inflammatory properties and to lead 
to improvements in tissue health and function [7–9]. The ability of SC to self-replicate, 
differentiate, prevent apoptosis and reduce inflammation has raised interest in the potential 
therapeutic value of these cells in NEC.
Types of Stem Cells (Figure 1)
Early stem cell research focused on embryonic stem cells (ESC), totipotent cells derived 
from embryos in mice [10]. Subsequent work showed that these same cells could be derived 
from human embryos. These human ESC (hESC) were also totipotent, however ethical 
concerns limited the research that could be done with hESC and researchers continued to 
search for alternative sources of stem cells.
Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC)
Bone marrow-derived cells have been studied extensively in both animals and humans. They 
can be readily derived from human donors without being encumbered by the ethical 
challenges faced by ESC. The culture process is straight-forward: marrow is harvested from 
long bones of donors and placed into culture to select for MSC [11]. As the cells are 
cultured, they must be passaged several times in order to minimize contamination with 
hematopoietic precursors that are present in the initial marrow sample. Confirmation of the 
presence of CD44 and CD90 on cells, and the absence of cells expressing CD45, helps to 
confirm that the cell population of interest is composed of MSC. BM-MSC derived from 
mice, rats and humans have been shown to be effective in reducing the incidence and 
severity of NEC in mouse and rat models [11–14].
Amniotic Fluid-derived Stem Cells
The first report of successful culture and expansion of mesenchymal stem cells from 
amniotic fluid (AF) was published in 2003 [15]. These cells not only express surface 
markers typical of mesenchymal stem cells (MSC) such as CD29, CD44, and CD90 among 
others, but they also express stage-specific embryonic antigen (SSEA)-4 and the 
transcription factor Oct4, both of which are associated with ESCs and not MSCs, and help to 
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ensure that the cells remain undifferentiated. It appears that AF-MSCs may be closer to 
embryonic in nature than other types of MSCs, which may contribute to their enhanced 
pluripotency and growth. De Coppi et al isolated human and rodent amniotic fluid-derived 
stem (AFS) cells that express both embryonic and adult stem cell markers [16]. AFS cells 
can be induced to form cells from all three germ layers, but have not been demonstrated to 
be tumorigenic [17, 18].
In addition to their promising properties, collection and culture of AF-MSC is straight-
forward and easily translated to humans. These cells can be cultured from AF samples 
collected during routine amniocentesis or at planned caesarean section [17, 18]. After 
collection, these cells can be cultured in media with few supplements and grow rapidly and 
reliably [11]. In comparison to BM-MSC, AF-MSC grow significantly faster and can be 
more easily and readily cultured and expanded into clinically useful cell numbers.
Since their discovery, interest in these cells has remained high. Intraperitoneal (IP) injection 
of AF derived stem cells has been shown to significantly reduce the incidence and severity 
of NEC in a murine model [19]. Subsequent studies confirmed that IP injection of these cells 
significantly decreases histologic injury and leads to improved gut barrier function during 
experimental NEC [11, 20].
Beneficial effects of AF have also been identified when experimental models utilize whole 
AF without purification of AF-derived cells. Both mice and pigs that received whole AF via 
enteral administration have significant protection from experimental NEC [21, 22] The 
concentration of stem cells in whole AF is generally low, on the order of 1–2% of cellular 
content, however this appears to be enough to have a positive effect, with the fluid 
functioning as a modulator of inflammation in the gut [19, 22].
Other Birth-Associated Mesenchymal Stem Cells (U-MSC, P-MSC)
Both the umbilical cord and the placenta have been recently appreciated as bountiful sources 
of mesenchymal stem cells. These cells are typically thought to be a more primitive 
progenitor population compared to adult tissue-derived MSC [23]. Umbilical cord blood-
derived MSC (U-MSC) can be isolated with relatively high efficiency through cell culture, 
with best results noted from blood that is less than 15 hours old and with a total volume of 
over 33 mL [24]. Other groups have demonstrated success with direct culture of pieces of 
the umbilical cord [25, 26]. U-MSC have been shown to be as beneficial as other types of 
MSC in acute intestinal ischemia [27]. Placental MSC (P-MSC) are also relatively easy to 
obtain through culture of the products of placenta tissue digestion. Like AF-MSC, these cells 
are positive for MSC markers as well as typical ESC-associated cell markers, indicating 
their high potential for differentiation [28]. Both U-MSC and P-MSC have been successful 
in preventing injury in animal models of ischemia [29, 30]
All birth-associated stem cell products represent a unique opportunity for autologous cell 
use in at-risk infants. Potentially, these tissues could be harvested during delivery of any 
premature infant or infant delivered via C-section for isolation and preservation in 
preparation for future administration.
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Amniotic Fluid-derived Neural Stem Cells (AF-NSC)
Although much research has focused on the use of MSC in NEC therapy, there are 
significant changes to the enteric nervous system (ENS) that occur during the development 
of NEC [31]. This has led to the investigation of neural stem cells (NSC) as a therapy for 
NEC. NSC can be cultured and isolated from AF and selectively grown. The culture process 
is somewhat more complicated than that of AF-MSC, and the cells do not grow as quickly. 
In brief, AF is collected in a similar fashion as for AF-MSC. The culture medium into which 
the cells are placed is significantly different for AF-NSC – the presence of epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) helps to ensure that NSCs remain in an 
undifferentiated state [11]. This process also helps to minimize the likelihood of survival of 
other SC that are present in AF. As the cells develop and grow, they begin to aggregate into 
neurospheres, which contain predominantly NSC. These neurospheres can be mechanically 
separated to isolate individual NSC. These cells tend to grow more slowly than MSC, and it 
can take several weeks before usable quantities of cells are available. After culturing, AF-
NSC identity can be confirmed by the expression of nestin, an intermediate filament protein 
present in developing NSC but downregulated when the cells become mature neural cells 
[32]. AF-NSC have been shown to have beneficial effects in animal models of ENS-based 
conditions such as Hirschsprung disease, and are also effective at reducing the incidence and 
severity of experimental NEC when injected IP [11].
Enteric Neural Stem Cells (E-NSC)
The complexity of the ENS and its interactions with the central nervous system (CNS) have 
become better understood in recent years, with a very high concentration of nerve endings 
and NSC located within the gut [33]. ENS abnormalities have been identified in infants 
diagnosed with NEC [31]. Interestingly, these ENS abnormalities last long after recovery 
from the acute NEC event.
E-NSC derived from the gut have similar properties to AF-NSC, and the culture medium 
used to support the growth of the cells is of the same composition. E-NSC are somewhat 
more challenging to obtain, with current experimental protocols purifying these cells 
through a combination of mechanical and enzymatic digestion of the gut to obtain E-NSC 
from the muscular layer of the small intestine [11]. After digestion, the cells are placed into 
culture to allow NSC to replicate and form neurospheres. These neurospheres can then be 
mechanically separated to yield individual NSC, which can be confirmed positive for nestin 
expression. E-NSC administered IP have been shown in several studies to be beneficial in 
treating experimental NEC and improving gut barrier function in these animals [11, 20, 31, 
34].
Stem Cell Mechanisms of Action (Figure 2)
Migration and Engraftment
Stem cells have the unique ability to migrate and home to injured tissues and organs. 
Additionally, because stem cells are multipotent, they are able to differentiate into multiple 
cell types, including intestinal epithelia, endothelia, and connective tissue cells [16, 35, 36]. 
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Therefore, stem cell transplantation may contribute to repair directly by integrating into the 
damaged tissue and replacing the injured cells.
Stem cells can travel to a wide variety of tissues with a high level of engraftment, 
particularly in the presence of injury or inflammation; however, the mechanism of this 
phenomenon is not yet fully understood [37]. It is possible that injured tissues express 
specific receptors or ligands that facilitate trafficking, adhesion, and infiltration of stem cells 
to the site of injury [38]. The intestine of premature neonates with NEC responds to injury 
by activating molecular pathways that increase the release of inflammatory mediators, tissue 
chemokines, and chemokine receptors, which may attract stem cells to the damaged 
intestine, where they may home and differentiate [39].
In normal rat pups, the intra-peritoneal administration of AFS cells leads to the migration, 
homing and integration of AF-MSC into the intestine, kidneys, liver, and spleen [40]. In the 
rat pup NEC model, within 48 to 72 hours after intraperitoneal injection, the AFS cells 
adhered to the mesentery and migrated to the intestinal serosa, smooth muscle, submucosal 
layers, and to the villi. Colonization with AFS cells occurred almost exclusively in the 
intestine of the pups with experimental NEC, indicating that AFS cells preferentially 
localize to damaged tissue [19]. Similarly, a previous study in experimental NEC 
demonstrated that intra-peritoneal administration of human BM-MSC exhibited high 
engraftment in the injured intestine resulting in reduced intestinal damage [13]. Once cells 
are engrafted, they can either directly differentiate to replace damaged cells, or interact with 
native intestinal stem cells (ISC) to upregulate the Wnt/β-catenin pathway as discussed 
below, which promotes auto-regeneration of intestinal epithelium [19].
Paracrine Effects
Although stem cells have a systemic distribution and integration into tissues, the beneficial 
effects seen after administration occur within hours of injection at a time when the amount 
of stem cells in the intestine is still relatively low. It seems more likely that the SC secrete 
anti-inflammatory mediators that enhance the host tissue’s ability to repair itself [8]. SC may 
act indirectly via the release of factors that support the regeneration of damaged cells, 
suggesting a predominantly paracrine effect [13, 19]. This has been shown in models of 
NEC and in numerous other disease processes including neurologic injury, ischemia-
reperfusion injury [8, 9].
Most studies of SC efficacy have examined individual cell types in their ability to protect the 
intestines from NEC. However, given the observation that these cells appear to function 
through reducing inflammation, it is possible that cells harvested from different tissues may 
ultimately have similar effects. In ischemia/reperfusion injury, BM-MSC and umbilical cord 
U-MSC were shown to have similar effects [27]. When comparing AF-MSC, BM-MSC, AF-
NSC, and E-NSC in a rodent model, all four cell types equivalently reduced the incidence 
and severity of experimental NEC [11]. These studies support the notion that there may be 
mediators common to multiple SC types that are responsible for their beneficial effects.
Conditioned media can be generated by placing stem cells into culture for several days, 
allowing their extracellular products to accumulate in the media, and then centrifuging to 
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remove the cells. In animals that received an IP injection of this conditioned medium, a 
statistically significant reduction in NEC was observed equivalent to the reduction seen 
when animals were treated with the same kind of SC [19].
Zani et al have shown that AFS cells may act via a paracrine mechanism related to 
cyclooxygenase-2 (COX-2) activity [19]. An increased migration of COX-2+ cells into the 
crypts was observed after AFS cell injection, which was inversely correlated with intestinal 
damage. Furthermore, COX-2 inhibitors abolished the protective effects of AFS cells, 
confirming that AFS cells act in a COX-2-dependant manner to attenuate the NEC injury 
[19].
Similarly, BM-MSC produce many soluble mediators such as cytokines, growth factors, 
microRNAs, and exosomes [41], which may be responsible for their beneficial effect of 
attenuating the NEC related injury. It has been shown that MSCs can increase intestinal 
epithelial cell viability and proliferative capacity via the paracrine release of IL-6, HGF, and 
VEGF, after hypoxic injury [42].
Stem cell-derived exosomes are nanovesicles 30–100 nm in size that are released by 
exocytosis into the extracellular space and can be purified from conditioned media through 
commercially available kits or by differential ultracentrifugation [43, 44]. They contain 
various types of RNA (including microRNAs important in post-translational gene 
regulation), DNA, and protein, and are important paracrine factors mediating cell-cell and 
cell-environment communication [45, 46]. Recently, Rager et al. isolated exosomes from 
BM-MSCs and tested their effects in a neonatal rat model of NEC. They found a reduction 
in incidence and severity of NEC as well as preserved gut barrier function [12]. Stem Cell 
derived exosomes also function as mediators of inflammation [44].
Further work is needed to understand the precise mechanisms by which SC and SC-derived 
exosomes exert their beneficial effects in NEC. It may be possible to identify specific 
components in the extracellular milieu or within the nanovesicles that are the driving factors 
in these effects. These components could subsequently be isolated and purified and used 
therapeutically without the theoretical risks associated with stem cell based therapies.
Heterotopic Cell Fusion
Heterotopic cell fusion is a third mechanism by which stem cells may provide their 
beneficial effects. It occurs when two cells from different lineages merge into one cell, 
transmitting information and mediators in the process [47]. Fusion has been demonstrated 
with BM-MSC and hepatocytes, Purkinje neurons, and cardiac myocytes [48], but the data 
in intestinal injury have not been convincing. Some studies have demonstrated fusion events 
between BM-MSC and intestinal epithelial cells [49], however others have noted that this is 
so rare that it is likely not the mechanism by which these cells are providing protective 
effects [50].
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Beneficial Effects of Stem Cells
Preservation of Intestinal Barrier Function
While the mechanisms are still in question, stem cells certainly provide significant benefit to 
the intestine in NEC. The intestinal epithelium is the most important barrier preventing the 
passage of foreign antigens and toxins from the external environment into the systemic 
circulation [51]. Preterm infants have diminished intestinal barrier function, leading to 
increased intestinal permeability. This may allow pathogens to translocate from the intestinal 
lumen and trigger the exuberant inflammatory response that characterizes NEC [52].
One of the potential beneficial effects of stem cell administration in NEC is the 
reestablishment of intestinal epithelial integrity. In the rat pup NEC model, all four stem cell 
types preserve and maintain intestinal epithelial integrity [20]. Previous studies have 
demonstrated that heparin-binding EGF-like growth factor (HB-EGF) promotes neural stem 
cell (NSC) proliferation and migration, and that both HB-EGF and NSC reduce intestinal 
injury, improve gut barrier function, and enhance intestinal motility in experimental NEC 
[34]. In addition, BM-MSC and BM-MSC-derived exosomes preserve intestinal 
permeability during NEC induction [12, 13]. MSC administration reduces bacterial 
translocation in NEC, indicating the protective role MSCs have in barrier function [13]. 
Similarly, AFS cell administration during experimental NEC improves intestinal barrier 
function and attenuates intestinal injury [19].
Attenuation of Inflammation
Inflammation is an important contributing factor in the pathogenesis of NEC [53]. TLR4 
signalling in the gut is required to maintain intestinal homeostasis and triggers the immune 
response to Gram-negative bacterial translocation. Activated TLR4 signalling is associated 
with NEC in mice, rats, and premature infants [54, 55]. AFS cells have been shown to 
reduce gut inflammation during NEC, however the mechanism of this action is not fully 
understood [19]. Stem cells secrete a wide variety of cytokines and chemokines that have 
beneficial actions during tissue repair [56, 57], to offset TLR4-induced intestinal 
inflammation [58, 59]. MSC also reduce gut inflammation and epithelium damage during 
NEC induction [13].
Promotion of Intestinal Regeneration
To maintain the integrity and viability of the epithelial layer, intestinal epithelial cells are in 
constant turnover and are replenished by intestinal stem cells (ISC). These cells, located in 
the intestinal crypts, are rapidly proliferating and critical for the intestinal epithelial 
regeneration that follows injury [60–62]. The ISC population is depleted in NEC 
proportionally to the severity of intestinal damage, indicating the crucial role of ISC in 
intestinal repair [63, 64]. AFS cells enhance enterocyte proliferation and improve epithelial 
regeneration [19], indicating cross-talk between exogenous stem cells and endogenous ISC.
NEC is associated with Wnt/β-catenin pathway dysfunction; this pathway is required for 
ISC function and gut epithelial maintenance [19, 65]. AFS cell administration led to 
upregulation of gene expression of the Wnt/β-catenin pathway, suggesting that this could be 
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a potential mechanism by which AFS cells contribute to intestinal regeneration [19]. 
Similarly, MSCs have been shown to upregulate growth factors which protect intestinal stem 
cells, maintain gut epithelial regeneration and reduce mucosal injury [14, 66].
Clinical Applications
Premature infants have relatively high levels of circulating hematopoietic stem cells at birth 
compared to term infants[67]. Since stem cells protect and heal injured tissues, those babies 
with suboptimal cell counts may be at increased risk for developing NEC. Relative stem cell 
deficiency could be due to an overall paucity of stem cells, dysfunctional stem cells, or an 
inability to mobilize functional stem cells to areas of injury. Mouse studies have 
demonstrated an increase in circulating stem cells after major intestinal resection or injury, 
indicating that stem cell mobilization is a native protective response in this patient 
population [68]. Therefore, it is reasonable to expect that providing exogenous stem cells to 
affected patients would promote intestinal healing and decreased injury during NEC [35, 
69].
Route of Administration
Based on previous studies in both NEC and intestinal ischemia-reperfusion injury, direct 
application of cellular therapy to injured or at-risk bowel may be more optimal compared to 
systemic intravenous or intraarterial administration [70–72]. As previously discussed, a 
likely mechanism of action of the stem cells is through the paracrine release of vital 
mediators. Thus, applying the stem cells directly to the injured bowel may be the most 
effective way to deliver the cell products at the highest local concentrations and improve 
recovery in the injured intestine [42].
In previous human studies for other conditions, systemic adverse effects such as infections 
and viral reactivation secondary to immune suppression occurred less frequently with local 
application of cells as compared to systemic application [73, 74]. Although both IP and 
intravenous (IV) routes of administration had equivalent efficacy in an animal model, many 
cells become entrapped in the lungs after IV injection, leading to a reduction in the number 
of cells available for therapeutic purposes [14, 75, 76].
Patient Selection-Therapy
The significant variation in NEC disease course makes decisions regarding timing of 
treatment with cellular therapy difficult [77]. Ideally, stem cell therapy would be provided to 
infants who have definitive NEC but who have not progressed to the point of requiring 
surgical intervention. Currently this would include Bell’s Stages II A, II B, and IIIA. 
However, given that many infants with stage IIA NEC recover with observation and bowel 
rest alone, the use of stem cell therapy in infants with non-surgical NEC beyond stage IIA 
may be considered optimal to limit progression of disease.
Although infants who present with perforation require surgical resection of the perforated 
and necrotic segments, they also may be able to be treated with stem cell therapy for other 
areas of the intestine that appear marginally ischemic at the time of surgery. Optimal patients 
for initial trials would be those with marginally ischemic bowel who will require 
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reassessment at a second-look operation [35, 77]. Since these infants already require 
multiple operations, no additional procedure would be needed to directly administer stem 
cells or to monitor their effects. Goals of therapy in this group would be to mitigate ongoing 
ischemia and necrosis and avoid the need for further resection at the second look operation. 
These patients represent an important subset of the population who could most benefit from 
this therapy, and would be an ideal first patient population to study.
Patient Selection-Prophylaxis
The prophylactic administration of stem cells to extremely premature infants with high risk 
for development of NEC could also be considered. A recent systematic review of prognostic 
studies identified many risk factors for NEC. Significant prognostic factors identified in 
multivariable analysis included low birth weight, early gestational age, sepsis, ethnicity, 
hypotension, outborn status, need for assisted ventilation, premature rupture of membranes, 
and small size for gestational age. Low birth weight (≤1500g) was the most commonly 
reported prognostic factor, which is likely linked to gestational age (studies varied from <36 
weeks to <26 weeks) [78]. If prophylactic or early stage therapy were to be considered, these 
risk factors would be useful in determining the most at-risk population.
Ethically, however, it would be challenging to justify the administration of cellular therapy 
to patients without definitive disease due to the perceived risks of tumorigenicity and 
immunogenicity as discussed below. Importantly, as discussed previously, acellular therapy 
could be administered without risk of these complications associated with cellular 
formulations. Because it is very likely that stem cells are acting in a paracrine fashion, 
delivery of exosomes or another secreted mediator could be equally effective, as shown in 
animal models [12, 44].
Use of Stem cell therapy for treatment of long-term NEC sequelae
Another important use of stem cell therapy would be in preventing or treating short bowel 
syndrome (SBS), often a long-term complication of NEC secondary to extensive bowel 
resection [69]. Unfortunately, despite surgical techniques such as the serial transverse 
enteroplasty and Bianchi procedures, which are aimed at lengthening the intestine and 
expanding the functional epithelial surface area, SBS remains a difficult disease to manage. 
Rehabilitation of injured bowel and/or integration of new functional bowel into an SBS 
patient would be groundbreaking.
Stem cell therapy alone may be able to improve intestinal epithelial absorptive function and 
bowel adaption, both of which are extremely important in recovery from SBS [35, 79]. For 
more severe cases, a stem cell-engrafted neo-intestine could be considered to provide length 
either at the time of initial resection or later in treatment, to allow the SBS patient to achieve 
freedom from parenteral nutrition [79]. A promising study in rats has demonstrated the 
feasibility of creating decellularized small bowel, leaving the villus-crypt architecture intact 
and able to be repopulated with new intestinal stem cells [80]. Intestinal organoids have been 
cultured in-vitro and subsequently administered back to rats, thereby resulting in renewal 
and repair of the grafted intestinal epithelium [81].
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The creation of these decellularized grafts led to development of functional tissue-
engineered small intestines which have been anastomosed with native bowel in piglets. Graft 
therapy resulted in weight gain and improved recovery after bowel resection [82]. More 
recently, a study in dogs demonstrated that intestinal crypt cultures can grow and 
differentiate into functional, vascularized bowel on 3D synthetic tubularized villous 
structures, and this neo-intestine can integrate into existing intestine and support native 
mucosal regeneration [83].
Human cadaver donor intestine has also been decellularized and reconstituted with BM-
MSC. The neo-intestine was found to have epithelial, smooth muscle, and endothelial cells 
and morphology similar to normal intestine [84]. While these haven’t been re-implanted into 
humans yet, the results are quite promising.
Safety Considerations
Tumorigenicity is a major concern in stem cell therapy. The same molecular pathways that 
allow a cell to be pluripotent are involved in tumorigenicity, and therefore more 
differentiated stem cells have a lower risk of this complication. Stem cells with a capacity 
for rapid growth but a low incidence of spontaneous differentiation are ideal for avoiding 
these complications. Neither AF-MSC nor BM-MSC have been shown to have high tumor 
formation potential in animal models [17, 18, 85, 86]. In fact, a recent systematic review 
looking at 36 clinical trials found no association between MSC administration and de novo 
tumor formation or increased susceptibility to infection [87]. This meta-analysis suggests the 
potential benefit of MSC therapy outweighs the potential risk, and that these theoretical risks 
may be less significant than previously believed.
Alternatively, recent work has indicated that human pluripotent stem cells have the capacity 
to develop loss-of-homozygosity mutations at the p53 locus, potentially increasing risk of 
cancer formation and demonstrating that comprehensive genetic testing may be necessary 
before cell therapy [88].
Immunogenicity is another potential adverse outcome of stem cell therapy. It can be reduced 
by autologous cell transfer or use of stem cells that have low expression of major 
histocompatibility complex (MHC) such as MSC [89]. Nevertheless, these risks cannot be 
eliminated, and thus the risks and benefits of this therapy need to be carefully considered.
Lastly, intravenous administration of stem cells has been demonstrated to cause trapping of 
cells within the lung parenchyma with sarcoma like lesions in the lungs in mice [90, 91]. 
Fortunately, this effect is lessened with intraperitoneal administration, another factor in favor 
of direct application.
Future Directions
The collective goal of clinicians and translational researchers in the field of stem cell therapy 
for the treatment of NEC is to progress to human clinical trials for stem cell delivery. There 
are several limitations to overcome before this can become a reality. First, regulatory hurdles 
to ensure safety for an extremely vulnerable population will need to be carefully addressed.
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Secondly, as discussed earlier, it is challenging to determine which patients will benefit the 
most from this therapy. We would propose starting first with the surgical NEC population, 
Bell’s stage III – those patients who require one or multiple trips to the operating room for 
bowel resection. The stem cell therapy could be delivered directly to injured bowel 
intraoperatively and assessed at future operations or by clinical improvement in the patients. 
In this population, there is little risk of providing unnecessary treatment, with great potential 
for benefit.
A third concern is the long-term implications of cellular therapy as discussed above. The 
ability of these cells to transform into malignant cells over time has been a long-time 
concern, despite evidence that the therapeutic benefits likely outweigh these risks [86].
Lastly, we still do not understand the full extent of their mechanisms of action. If stem cells 
protect by paracrine mechanisms, which factors are most important? How many factors need 
to be present? And most importantly, if paracrine factors are the key to protection, could an 
acellular cocktail be made of these factors to avoid the need for a cellular based therapy 
altogether? These questions need to be answered before widespread clinical use.
Conclusions
Stem cell therapy is promising as a treatment for necrotizing enterocolitis. It is likely that AF 
derived stem cells or BM-MSC will be the most useful and practical cell-based therapies for 
this condition. Acellular therapies such as exosomes or other paracrine mediators still to be 
identified are promising as well. Multiple mechanisms are likely at play in the positive 
effects provided by these cells, and further research is underway to fully understand these. 
Moving to human clinical trials is feasible and reasonable, and with good patient selection, 
success is anticipated.
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Figure 1. 
Different types of stem cells available for NEC treatment. Embryonic, while able to 
differentiate into any tissue, are not used due to ethical concerns with their procurement 
from the inner mass of the blastocyst of human embryos. Amniotic fluid can give rise to 
embryonic stem cells as well. Both mesenchymal stem cells and neural stem cells have been 
used with success in animal models of NEC.
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Figure 2. 
Mechanisms by which mesenchymal stem cells work to protect the intestine against NEC. 
Beneficial effects provided by stem cells are likely achieved through one or more of these 
pathways. A) MSC homing, engraftment and differentiation. B) Paracrine release of anti-
inflammatory mediators, exosomes, microRNA, and/or cytokines. C) Heterotopic cell fusion 
with direct transfer of cellular biomaterials.
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